IMA901: Additional Phase II data
Additional data from the open-label, exploratory, European Phase II IMA901-202 trial in 61 evaluable patients with advanced or metastatic RCC who had failed previous first-line therapy showed that intradermal IMA901 led to significantly greater survival in patients who were positive for 1 or both of the chemokine CC motif ligand 17 (CCL17) and apolipoprotein A-1 (APOA1) biomarkers (n=44) vs. patients who were negative for both markers (n=17; p=0.0001). In patients pretreated with cyclophosphamide, median OS was >26.1 months in patients who were positive for both biomarkers, 21.6 months in patients who were positive for 1 of the markers, and 7.3 months in patients who were negative for both markers. Patients received intradermal IMA901 plus granulocyte macrophage colony-stimulating factor (GM-CSF) with or without cyclophosphamide. Data were presented at the Association of Cancer Immunotherapy meeting in Germany. ...